EUCTR2009-011992-61-ESActive, not recruitingNot Applicable
Ensayo de fase II, aleatorizado, del inhibidor de MEK AS703026 o placebo en combinación con gemcitabina, en pacientes con cáncer de páncreas metastásico no tratados previamente con quimioterapia.
Merck Serono S.A. - Geneva0 sites143 target enrollmentStarted: August 14, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 143
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Subject fully understands requirements of the trial, is willing to comply with all trial visits and assessments, has provided written informed consent.
- •Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas and availability of tumor sample (archived or fresh biopsy).
- •Evidence of disease (not necessarily measurable disease) as per complete tumor assessment performed within 28 days prior to trial entry/randomization.
- •Age 18 years and older.
- •Women of childbearing potential must have a negative blood pregnancy test at the screening visit.
- •Willingness to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to, during and four weeks after the last dose trial medication as applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Bone marrow impairment as evidenced by hemoglobin < 9.0 g/dL, neutrophil count < 1.5 x 10^9/L, platelets < 100 x 10^9/L.
- •Renal impairment as evidenced by serum creatinine > 1.5 x upper limit of normal (ULN), and/or calculated creatinine clearance < 60 mL/min.
- •Liver function abnormality as defined by total bilirubin > 1.5 x ULN, or AST/ALT > 2.5 x ULN, for subjects with liver involvement AST/ALT > 5 x ULN.
- •Serum calcium > 1 x ULN.
- •History of central nervous system (CNS) metastases, unless certain prerequisites are met.
- •History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions that may hamper compliance and/or absorption of the tested product.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) greater than 1.
- •Known HIV positivity, active hepatitis C, active hepatitis B or signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
- •Prior chemotherapy, other than allowed
- •Extensive prior radiotherapy or prior bone marrow/stem cell transplantation. Prior radiation for local disease management is allowed under certain circumstances.
- •History of any other significant medical disease that might impair the subjects well being or preclude full participation in the trial.
- •Significant cardiac conduction abnormalities and/or pacemaker.
- •Pregnant or nursing female subject.
- •Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion.
- •Known hypersensitivity to the AS703026 or gemcitabine.
- •Participation in another clinical trial within the past 28 days.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Randomized Phase II Trial Assessing Atezolizumab in Locally Advanced Cervical Cancerocally Advanced Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-003622-33-FRGustave Roussy190
Active, not recruiting
Phase 1
Ensayo Clínico, fase II aleatorizado de tratamiento neo-adyuvante con 2 ciclos de temozolomida a dosis extendidas, previos al tratamiento con temozolomida más irradiación y posterior adyuvancia con temozolomida vs mismo tratamiento con bevacizumabGlioblastoma no resecableEUCTR2009-010337-45-ESGRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA90
Active, not recruiting
Phase 1
Etude de phase II, randomisée, testant l'association Nexavar (sorafenib) gemcitabine et oxaliplatine (GEMOX) dans le traitement des carcinomes hépatocellulaires non accessibles à un traitement chirurgical ou locorégional GONEXT - GONEXTCarcinome hépatocellulaire non accessible à une chirurgie ou à une destruction per-cutanée.MedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-000123-26-FRCentre Val d'Aurelle Paul Lamarque
Active, not recruiting
Not Applicable
Ensayo clínico fase II aleatorizado de cotratamiento con hormona de crecimiento recombinante humana dentro de un protocolo largo de estimulación ovárica bajo agonista de GnRH en mujeres con pobre respuesta ovárica previa - GH en pobres respondedoras de FIVEUCTR2010-022151-32-ESFUNDACION SANTIAGO DEXEUS FONT
Not yet recruiting
Phase 2
Clinical trial of Methotrexate associated to Hydroxyurea versus placebo and Hydroxyurea in patients with sickle cell diseaseRBR-57qbjvCentro Infantil Boldrini